|Expense Ratio (net)||0.82%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||Below Average|
|Beta (5Y Monthly)||1.00|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Apr 01, 1948|
PETERBOROUGH COUNTY, ON, March 17, 2021 /CNW/ - Members of the accredited media are invited to join the Eastern Ontario Regional Network (EORN) for an announcement about cellular connectivity. Other participants include: The Honourable Maryam Monsef, Canada's Minister for Women and Gender Equality and Rural Economic Development; The Honourable Laurie Scott, Ontario's Minister of Infrastructure; Warden J.
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA, ON, March 2, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the "Units") of the Company.
Company signs LOI for Nordics and GermanyOTTAWA, ON / ACCESSWIRE / February 25, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland, and Germany.